News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Kerry Segal Appointed Vice President, Business Development, At Immuno-Designed Molecules


10/19/2005 5:10:15 PM

PARIS--(BUSINESS WIRE)--Nov. 4, 2003--IDM (Immuno-Designed Molecules), a biopharmaceutical company specialized in the field of cellular immunotherapy, announces that Kerry N. Segal has joined the company as Vice President, Business Development. Mr. Segal will be based in Irvine, Calif., where IDM U.S. operations are located.

Mr. Segal is a senior professional in business development, licensing and acquisitions, and brings to IDM approximately 20 years of diverse industry experience in pharmaceutical and biotechnology companies.

Prior to joining IDM, Mr. Segal held the position of Director, Licensing and Acquisitions, at Cephalon, Inc. since 1998. In this position, he was responsible for global licensing, negotiation of agreements and corporate merger/acquisition strategy.

Previously, Mr. Segal worked at several companies in the U.S., including Novartis, Johnson & Johnson, Sandoz Pharmaceuticals, Elkins-Sinn Pharmaceuticals and Bristol Labs Pharmaceutical in various positions in business development, sales and marketing.

Mr. Segal holds an MBA from Temple University.

"We are delighted to welcome Kerry Segal. His expertise in large biotech and pharmaceutical companies will be a critical asset for IDM's development while we continue to search for new international partnerships," said Jean-Loup Romet-Lemonne, President and CEO.

IDM - The Immunogenics Company®

IDM is a leading biopharmaceutical company developing a new family of immunotherapy products called Cell Drugs to fight cancer and other life-threatening diseases. IDM applies its proprietary technologies to selectively isolate, engineer, expand and activate specific cell populations which are involved in therapeutic vaccination. The Company's products are designed to boost the immune system, destroy residual tumor cells, and immunize patients to prevent tumor recurrence.

For more information, please visit IDM's Web site, http://www.idm-biotech.com

IDM Paris Headquarters 172 rue de Charonne

75545 Paris Cedex 11

FRANCE

tel +33 (0) 1 40 09 04 11 fax +33 (0) 1 40 09 04 25 e-mail idm@idm-biotech.com

Contact:

IDM Nadine Sciacca, +33 (0) 1 40 09 04 11 (Press) nsciacca@idm-biotech.com

Source: Immuno-Designed Molecules


Read at BioSpace.com


comments powered by Disqus
IDM S.A.
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES